SG10201906400SA - Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof - Google Patents
Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereofInfo
- Publication number
- SG10201906400SA SG10201906400SA SG10201906400SA SG10201906400SA SG10201906400SA SG 10201906400S A SG10201906400S A SG 10201906400SA SG 10201906400S A SG10201906400S A SG 10201906400SA SG 10201906400S A SG10201906400S A SG 10201906400SA SG 10201906400S A SG10201906400S A SG 10201906400SA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- methods
- pharmaceutical compositions
- ppar agonists
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562238629P | 2015-10-07 | 2015-10-07 | |
US201562243263P | 2015-10-19 | 2015-10-19 | |
US201662352348P | 2016-06-20 | 2016-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201906400SA true SG10201906400SA (en) | 2019-08-27 |
Family
ID=57200096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201906400SA SG10201906400SA (en) | 2015-10-07 | 2016-10-05 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Country Status (26)
Country | Link |
---|---|
US (5) | US10399958B2 (fr) |
EP (3) | EP3359528B1 (fr) |
JP (2) | JP6657413B2 (fr) |
KR (2) | KR102667385B1 (fr) |
CN (3) | CN113004205B (fr) |
AU (3) | AU2016333963C1 (fr) |
BR (1) | BR112018006866B1 (fr) |
CA (1) | CA3000431A1 (fr) |
CO (1) | CO2018004473A2 (fr) |
DK (1) | DK3359528T3 (fr) |
EA (1) | EA037371B1 (fr) |
ES (2) | ES2906379T3 (fr) |
HK (1) | HK1257907A1 (fr) |
HU (1) | HUE058154T2 (fr) |
IL (3) | IL258225B (fr) |
JO (3) | JO3738B1 (fr) |
MA (2) | MA52098A (fr) |
MX (2) | MX2020011099A (fr) |
PH (1) | PH12018500762A1 (fr) |
PL (1) | PL3359528T3 (fr) |
PT (1) | PT3359528T (fr) |
SG (1) | SG10201906400SA (fr) |
TW (3) | TWI742479B (fr) |
UA (1) | UA122237C2 (fr) |
WO (1) | WO2017062468A1 (fr) |
ZA (4) | ZA201802029B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113004205B (zh) | 2015-10-07 | 2024-07-02 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
ES2861503T3 (es) | 2016-04-13 | 2021-10-06 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
MA46459B1 (fr) * | 2016-10-05 | 2021-03-31 | Mitobridge Inc | Méthode de traitement de lésions rénales aiguës |
JP7017563B2 (ja) | 2016-10-05 | 2022-02-08 | ミトブリッジ,インコーポレーテッド | Pparアゴニスト化合物の結晶性および塩形態 |
US20220331267A1 (en) * | 2019-09-05 | 2022-10-20 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2022189856A1 (fr) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Composés utiles pour le traitement des maladies du foie |
KR20240037940A (ko) | 2021-06-02 | 2024-03-22 | 아스테라스 세이야쿠 가부시키가이샤 | Ppar 작용제 화합물의 사용 방법 및 이의 약학 조성물 |
WO2023147309A1 (fr) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Utilisation d'agonistes ppar-delta dans le traitement d'une maladie |
EP4230196A1 (fr) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Composés à utiliser dans le traitement des dystrophinopathies |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
DE4123341A1 (de) | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
KR20020006626A (ko) | 1999-02-26 | 2002-01-23 | 폴락 돈나 엘. | 신규한 술폰아미드 화합물 및 그의 용도 |
GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
CN1443173A (zh) | 2000-08-17 | 2003-09-17 | 辉瑞大药厂 | 作为TAFIa抑制剂的取代的咪唑 |
WO2004020408A1 (fr) * | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles a activite antidiabetique |
TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
WO2004060367A1 (fr) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Derives d'imidazole et de triazole utiles en tant qu'inhibiteurs de cox-1 selectifs |
CA2554982A1 (fr) | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Procede pour inhiber la production de lipoproteines restantes |
JP2008512364A (ja) | 2004-09-06 | 2008-04-24 | エフ.ホフマン−ラ ロシュ アーゲー | 4−アミノメチルベンズアミジン誘導体及び第VIIa因子阻害剤としてのその使用 |
BRPI0606997A2 (pt) | 2005-02-15 | 2009-07-28 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa) e utilização dos compostos |
BRPI0615948A2 (pt) | 2005-09-07 | 2011-05-31 | Plexxikon Inc | composto ativo de ppar, sua composição, seu kit e seu uso |
NZ569329A (en) | 2006-01-30 | 2011-09-30 | Transtech Pharma Inc | Substituted imidazole derivatives and their use as PTPase inhibitors |
AU2007229637A1 (en) | 2006-03-28 | 2007-10-04 | Novartis Ag | Amide derivatives and their application for the treatment of G protein related diseases |
CN102643248A (zh) | 2006-04-18 | 2012-08-22 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
CN101085772A (zh) | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
JPWO2008093639A1 (ja) | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
US20100063041A1 (en) | 2007-03-07 | 2010-03-11 | Ho-Sang Moon | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
JP2008285452A (ja) | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | PPARα/γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
JP2011507970A (ja) | 2007-12-28 | 2011-03-10 | ザ ソーク インスティテュート フォー バイオロジカル スタディーズ | 筋肉の能力および緊張を向上させるための方法 |
EP2890313B1 (fr) | 2012-08-28 | 2016-09-21 | KOC Universitesi | Plaque à os |
WO2014165827A1 (fr) | 2013-04-05 | 2014-10-09 | Salk Institute For Biological Studies | Antagonistes de ppar |
WO2015035171A1 (fr) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Utilisation d'un agoniste de ppar-delta pour le traitement d'une amyotrophie |
WO2016057322A1 (fr) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Agonistes de ppar et leurs méthodes d'utilisation |
US20170305894A1 (en) | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
CN113004205B (zh) * | 2015-10-07 | 2024-07-02 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物及其使用方法 |
ES2861503T3 (es) | 2016-04-13 | 2021-10-06 | Mitobridge Inc | Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos |
JP7017563B2 (ja) * | 2016-10-05 | 2022-02-08 | ミトブリッジ,インコーポレーテッド | Pparアゴニスト化合物の結晶性および塩形態 |
MA46459B1 (fr) | 2016-10-05 | 2021-03-31 | Mitobridge Inc | Méthode de traitement de lésions rénales aiguës |
CN110167926B (zh) * | 2016-12-30 | 2022-09-13 | 米托布里奇公司 | 聚-adp核糖聚合酶(parp)抑制剂 |
-
2016
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/fr active Application Filing
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active IP Right Grant
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active IP Right Grant
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 CA CA3000431A patent/CA3000431A1/fr active Pending
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 MX MX2020011099A patent/MX2020011099A/es unknown
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/fr active Active
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 CN CN202110286947.3A patent/CN113024467A/zh active Pending
- 2016-10-05 MX MX2020011100A patent/MX2020011100A/es unknown
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 EP EP20193960.0A patent/EP3770146A1/fr active Pending
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/fr active Active
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
-
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
-
2019
- 2019-01-08 HK HK19100269.3A patent/HK1257907A1/zh unknown
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
-
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-09-14 JO JOP/2020/0230A patent/JOP20200230A1/ar unknown
- 2020-09-14 JO JOP/2020/0231A patent/JOP20200231A1/ar unknown
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
-
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
-
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200231A1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
MX2018012538A (es) | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos. | |
MX2021009673A (es) | Moduladores de ror-gamma. | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
MX2021007268A (es) | Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. | |
WO2016057658A8 (fr) | Agonistes de ppar, composés, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci | |
MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
WO2015171558A3 (fr) | Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie | |
MX2021002321A (es) | Nuevos metodos. | |
PH12017500261A1 (en) | Substituted bicyclic compounds | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
WO2018115432A3 (fr) | Composés pour le traitement d'une maladie respiratoire bovine ou porcine | |
WO2016004413A3 (fr) | Inhibiteurs de la gls1 pour le traitement de maladies | |
MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
WO2016057660A8 (fr) | Agonistes, composés, compositions pharmaceutiques ppar et méthodes d'utilisation de ceux-ci | |
EP3475442A4 (fr) | Composés d'acide 12(s)-hydroxyéicosatriénoïque et leur utilisation comme agents thérapeutiques | |
ZA202103209B (en) | Monohydrate potassium salt of a thienopyridone derivative and its preparation process | |
MX2023005014A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
MX2018004295A (es) | Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar. | |
EA201992619A2 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
UA112357C2 (uk) | Спосіб індивідуальної цільової терапії дефіциту вітаміну d у пацієнтів із захворюваннями кістково-м'язової системи | |
IN2014MU01184A (fr) | ||
IN2014MU01185A (fr) | ||
TH167851A (th) | (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค |